Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.

Abstract

Colorectal cancer is one of the most common malignant tumors and, hence, has become one of the most important public health issues in the world. Treatment with immune checkpoint inhibitors (ICIs) successfully improves the survival rate of patients with melanoma, non-small-cell lung cancer, and other malignancies, and its application in metastatic colorectal cancer is being actively explored. However, a few patients develop drug resistance. Predictive molecular markers are important tools to precisely screen patient groups that can benefit from treatment with ICIs. The current article focused on certain important predictive molecular markers for ICI treatment in colorectal cancer, including not only some of the mature molecular markers, such as deficient mismatch repair (d-MMR), microsatellite instability-high (MSI-H), tumor mutational burden (TMB), programmed death-ligand-1 (PD-L1), tumor immune microenvironment (TiME), and tumor-infiltrating lymphocytes (TILs), but also some of the novel molecular markers, such as DNA polymerase epsilon (POLE), polymerase delta 1 (POLD1), circulating tumor DNA (ctDNA), and consensus molecular subtypes (CMS). We have reviewed these markers in-depth and presented the results from certain important studies, which suggest their applicability in CRC and indicate their advantages and disadvantages. We hope this article is helpful for clinicians and researchers to systematically understand these markers and can guide the treatment of colorectal cancer.

• Authors: Fenqi Du, Yanlong Liu
• Journal: Journal of clinical laboratory analysis (J Clin Lab Anal) Vol. 36 Issue 1 Pg. e24141 (Jan 2022) ISSN: 1098-2825 [Electronic] United States
• PMID: 34817097 (Publication Type: Journal Article, Review)
• Copyright: © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.

Chemical References

• Biomarkers, Tumor
• Immune Checkpoint Inhibitors

Topics

• Biomarkers, Tumor (genetics)
• Colorectal Neoplasms (drug therapy, genetics, pathology)
• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Immunotherapy
• Precision Medicine